Skip to main content
Premium Trial:

Request an Annual Quote

Protagen, Qiagen Collaborate to Advance Development of Protein-based CDx for Autoimmune Diseases

NEW YORK (GenomeWeb) – Diagnostics firm Protagen announced a long-term collaboration agreement with Qiagen to provide pharmaceutical partners access to technology that would advance the development of protein-based companion tests for autoimmune disorders.

The terms of the agreement give Qiagen access to Protagen's proprietary SeroTag, an automated multiplex technology that can facilitate the discovery and validation of protein-based biomarker panels. SeroTag can measure autoantibody levels for thousands of antigens from a patient's single serum sample.

According to Qiagen, the technology can support Phase I to Phase IV drug development programs for autoimmune illnesses, as well as enable the development of companion tests for better disease diagnosis, patient stratification in clinical trials, and improved treatment strategies.

"The synergistic combination of the unique expertise of Qiagen and Protagen in the development and commercialization of companion diagnostics will offer a complete solution for pharmaceutical and biotech companies targeting the development of new therapeutic compounds, diagnostic, or companion diagnostic tests in the area of autoimmune disorders," the companies said in a statement.

Protagen and Qiagen did not disclose the financial details of their deal.

"Following cancer, autoimmune disorders are currently the second largest therapeutic area for companion diagnostics in drug development with a significant unmet medical need," Rainer Metzger, Qiagen's VP of business development pharma, noted in a statement.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.